** Shares of drug developer Annovis Bio ANVS.N drop 17.7% to $4.01 premarket
** ANVS announces pricing of public offering of 5.25 mln shares of common stock and warrants at $4/shr for gross proceeds of $21 mln
** Stock offering priced at a 17.9% discount to stock's last close
** ThinkEquity was the sole book-running manager for the offering
** ANVS plans to use the proceeds for working capital and general purposes, including the development of its lead experimental drug, Buntanetap
** Prior to offering, ANVS had ~14.3 mln outstanding shares, per SEC filing, giving it a market cap of $69.3 mln as of last close
** ANVS stock slumped 73.1% in 2024
(Reporting by Arasu Kannagi Basil in Bengaluru)
((ArasuKannagi.Basil@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.